PDF(Pubmed)
Abstract：
UNASSIGNED: This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma.
UNASSIGNED: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented.
UNASSIGNED: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring.
UNASSIGNED: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.
UNASSIGNED: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented.
UNASSIGNED: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring.
UNASSIGNED: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.
摘要：
■本报告旨在描述一个双边案例，erdafitinib治疗转移性尿路上皮癌期间发生的多灶性神经感觉视网膜脱离。
■提供了彩色眼底成像和谱域光学相干断层扫描成像的病例报告。
■一名患有转移性尿路上皮癌的50岁男性患者在开始服用埃达非替尼之前进行了不显著的基线眼科检查。在3个月的随访中，检查显示双边，多灶性视网膜脱离。因为患者无症状，erdafitinib是他的肿瘤唯一有反应的药物，在密切的眼科监测下，他一直在服药。
■Erdafitinib，成纤维细胞生长因子受体抑制剂，会导致双边，多灶性视网膜脱离。当药物的总体益处似乎超过风险时，没有明显视力障碍的患者可以考虑继续使用erdafitinib。
■提供了彩色眼底成像和谱域光学相干断层扫描成像的病例报告。
■一名患有转移性尿路上皮癌的50岁男性患者在开始服用埃达非替尼之前进行了不显著的基线眼科检查。在3个月的随访中，检查显示双边，多灶性视网膜脱离。因为患者无症状，erdafitinib是他的肿瘤唯一有反应的药物，在密切的眼科监测下，他一直在服药。
■Erdafitinib，成纤维细胞生长因子受体抑制剂，会导致双边，多灶性视网膜脱离。当药物的总体益处似乎超过风险时，没有明显视力障碍的患者可以考虑继续使用erdafitinib。
